Industry SectorsMarketsMerck Announces Second Round of Job Losses

Merck Announces Second Round of Job Losses

Pharmaceuticals manufacturer Merck has announced a further 8,500 job losses, on top of an earlier cut of 7,500 positions. It will also restructure its research and development (R&D), following delays by US regulators in approving new medicines. The company has now reduced its total workforce by 20%.

The cuts aim to achieve savings of US$1bn for Merck in 2014 and US$2.5bn per year thereafter, the company announced. Half of the savings will be achieved in R&D and the remainder in the company’s commercial division, including sales and marketing.

The moves are part of a strategy instigated by Merck’s chief executive officer (CEO), Ken Frazier and R&D chief Roger Perlmutter. The latter joined the company in April to replace Peter Kim, under whom experimental drugs in cardiovascular, surgery, and osteoporosis suffered setbacks while rival drugmakers were able to get new products to market.

“We will sharpen our focus on core therapeutic areas,” Frazier said on a conference call, indicating more resources for vaccines, cancer, diabetes and hospital care. “In other therapeutic areas, we will significantly reduce our resources.”

Commenting on the announcement, Warwick Business School professor John Lyon said that Merck’s restructure followed its peers, including Pfizer, AstraZeneca and GlaxoSmithKline. “There is a huge transformation going on in the pharmaceutical industry,” he commented

“Pharmaceutical companies can no longer rely on the blockbuster model of developing drugs and searching for revenues in excess of US$1m per year, so they need to look at innovative ways of generating new products.

“Clinical scientists have spent many years, decades, investigating new medicines from existing chemical compounds and proteins, but it is becoming more and more difficult simply because there are less to look at as the years go on. There is only a finite number of compounds, so the industry is having to shift its focus.

“I would suggest large pharmaceutical companies like Merck need more of the entrepreneurial mind-set within the corporation and also mirrored in their processes to feed their earnings per share year on year. Large corporations are very process driven, but they need to be more flexible and find new innovative ways of working in terms not only of their mindset, but also embedding that into new processes that work.

“They need to be more nimble, so that ownership and responsibility has moved down the organisation and they are not as hierarchical. But this takes time, it is an on-going process that will take many years – it is like turning an oil tanker.”

Related Articles

The trends set to define the fintech, banking and finance industry in 2020

Brexit The trends set to define the fintech, banking and finance industry in 2020

1m Pierre-Antoine Dusoulier
Frack attack: energy uncertainty and the need for agile credit risk

Credit Risk Frack attack: energy uncertainty and the need for agile credit risk

3m Ian Tobin
Finance functions must adapt to attract Generation Z talent

Financial Services Finance functions must adapt to attract Generation Z talent

7m Austin Clark
Financial professionals struggle to find time to combat stress

Financial Services Financial professionals struggle to find time to combat stress

2y The Global Treasurer
The Challenge of Building and Maintaining a Central Treasury Operation in a Decentralized Company

EEA The Challenge of Building and Maintaining a Central Treasury Operation in a Decentralized Company

2y BELLIN
The Treasury Challenge of a Post-Merger Integration

EEA The Treasury Challenge of a Post-Merger Integration

2y BELLIN
The Challenge of Integrating Worldwide Subsidiaries into one TMS

Baltics The Challenge of Integrating Worldwide Subsidiaries into one TMS

2y BELLIN
Q&A with BMG's treasury : BELLIN - We Love Treasury 2

EEA Q&A with BMG's treasury : BELLIN - We Love Treasury 2

2y BELLIN

Whitepapers & Resources

Transaction Banking Survey 2019

Transaction Banking Survey 2019

5m
TIS Sanction Screening Survey Report

Payments TIS Sanction Screening Survey Report

8m
Enhancing your strategic position: Digitalization in Treasury

Payments Enhancing your strategic position: Digitalization in Treasury

9m
Netting: An Immersive Guide to Global Reconciliation

Netting: An Immersive Guide to Global Reconciliation

1y